DameWave
Posted - 2 days ago
$FBIO Why Fortress is significantly undervalued (Part 100)? Look at Swedish Linc, which in terms of business is reminiscent of FBIO by co-owning several companies on and off the stock exchange in healthcare. Medcap/Stille is in a sense theirs $DERM and $CALT their $CKPT (actually believe much more in CKPT despite the huge valuation difference), but otherwise they mostly own Swedish biotech that are rubbish, and FBIO portfolio is much, much more attractive according to me. Linc's ownership is usually minority which means they can have low influence, while FBIO has a majority (founded by most) which means their control is high. Nevertheless, Linc is traded at 69 SEK, when their net value was 62 SEK (Q1). They trade at a premium, when FBIO is traded at a huge discount! Why premium? Swedish investors strongly believe in the founder/CEO and that his knowledge is worth more than owning a biotech/healthcare fund. Their CEO is nobody compared to the 3 who run Fortress. https://linc.se/?lang=en $XBI
S0887
Posted - 04/26/24
$CALT
Stock_Titan
Posted - 04/24/24
$CALT $CALTX Calliditas Therapeutics' 2023 Annual Report Published
https://www.stocktitan.net/news/CALT/calliditas-therapeutics-2023-annual-report-bln4z8x27nmm.html
Stock_Titan
Posted - 04/24/24
$CALT $CALTX Calliditas Announces Positive NefIgArd Open Label Extension Results
https://www.stocktitan.net/news/CALT/calliditas-announces-positive-nef-ig-ard-open-label-extension-rh17h4gviqo1.html
Stock_Titan
Posted - 04/18/24
$CALT $CALTX Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
https://www.stocktitan.net/news/CALT/calliditas-therapeutics-presents-additional-data-analyses-from-the-lagfdcy8t0j1.html
Squalewally
Posted - 04/16/24
$CALT FDA has granted an orphan drug exclusivity period of seven years for Tarpeyo, expiring in December 2030, based on when the company obtained full approval with a new indication for this drug.
squueeze
Posted - 04/16/24
$CALT $TVTX
squueeze
Posted - 04/15/24
$TVTX is poop. Look into $CALT instead
gerrard87
Posted - 04/15/24
$CALT eGFR for patients UPCR <=0,8g/g: Sparsentan/Filspari 25 months: -3,7 Nefecon/Tarpeyo 9 months + 15 months without: -1,7 Nefecon/Tarpeyo is without dought the better choice for patients with UPCR <=0,8. Will change the view how the KDIGO guidelines 2024 will end up!
gerrard87
Posted - 04/15/24
@squueeze Vertex has a great managment. They payed a lot of money. Yeah they are biased but competition is ramping up and $CALT is burning money with there other studies...
AJavier
Posted - 04/12/24
$CALT Good news but dumping.Why?
Pharmsci01
Posted - 04/11/24
@db4 IgA CKD is a big area with only one drug fully approved. Just surprised they didn’t BO $CALT .
gerrard87
Posted - 04/11/24
$CALT Tarpeo is not a disease-modifying drug. It is not a drug that targets the underlying cause of disease. And has very modest efficacy, its fair to say "COO/CEO Vertex Pharmaceuticals"
Stock_Titan
Posted - 04/09/24
$CALT $CALTX Calliditas Therapeutics to Attend Conferences in April
https://www.stocktitan.net/news/CALT/calliditas-therapeutics-to-attend-conferences-in-z9q343nfh2gn.html
squueeze
Posted - 04/08/24
$CALT buying today at open
Stock_Titan
Posted - 04/08/24
$CALT $CALTX Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
https://www.stocktitan.net/news/CALT/calliditas-therapeutics-to-present-nefecon-data-at-the-isn-world-h7ucchg36qsx.html
Stock_Titan
Posted - 04/08/24
$CALT $CALTX Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
https://www.stocktitan.net/news/CALT/calliditas-receives-notice-of-allowance-for-united-states-patent-ex4k5gf2w5df.html
Bigeyes2
Posted - 1 month ago
$CALT Swing
squueeze
Posted - 1 month ago
$CALT Anyone here?
squueeze
Posted - 03/18/24
$CALT dead money.. wtf
Stock_Titan
Posted - 03/11/24
$CALT $CALTX Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
https://www.stocktitan.net/news/CALT/everest-medicines-partner-calliditas-therapeutics-announces-u-s-fda-rh6zxmkbnq1c.html
PickStocker
Posted - 03/08/24
$CALT Bought a position. Should have bought already last week, but better late than never. Let's see where we are 5 years from now.
Yourmatefromdownunder
Posted - 03/06/24
$CALT Think we might start a spirited move upwards, been waiting for this.
Stock_Titan
Posted - 03/06/24
$CALT $CALTX Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
https://www.stocktitan.net/news/CALT/calliditas-announces-an-additional-seven-year-orphan-drug-d407y4mwbdb6.html
TickerDD_com
Posted - 2 months ago
From 3/1/2024, looking back across 22 Month-Ends for CALT, Percentage Change of Average Monthly Price had More Negatives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $CALT #CALT #CALTStock #TickerDD #CALTPrice https://www.youtube.com/watch?v=9IWYvJ-z1G0
coltsrock37
Posted - 2 months ago
$CALT @Pharmsci01 @PB9 @BullMarketStocks i love what i’m reading about with this company; i love how under-the-radar they are as well. thinking of buying options or straight shares depending on the week we’re going to have…any insights you can provide me besides what i’m reading about on their SEC filings, investor deck and corporate presentations? future looks bright 😎
Stock_Titan
Posted - 2 months ago
$CALT $CALTX Calliditas Therapeutics to Attend Investor Conferences in March
https://www.stocktitan.net/news/CALT/calliditas-therapeutics-to-attend-investor-conferences-in-08wbr4o3ueqp.html
BullMarketStocks
Posted - 02/27/24
$AGIO $ARDX $CALT love seeing my smaller bios catch 🔥 with the XBI 💪🏽
Pharmsci01
Posted - 02/22/24
$CALT CKD is a big therapeutic area with high demands. BPs are fighting in this area for drugs.